MET and cancer: Although crizotinib, a MET-targeted inhibitor, induced weak growth inhibition of A549-Luc-BM1 cells (GI50 value = 1.1 μM), this effect was considered to be independent of MET inhibition, because crizotinib displayed higher potency against cancer cells with MET amplification (e.g. MKN45, Hs746T, or NUGC4 cells) than against A549-Luc-BM1 cells [16].